Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at SVB Leerink

SVB Leerink upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a market perform rating to an outperform rating in a research report released on Thursday morning, MarketBeat reports. SVB Leerink currently has $45.00 target price on the medical device company’s stock, up from their prior target price of $34.00.

A number of other analysts have also commented on TNDM. Stifel Nicolaus boosted their target price on Tandem Diabetes Care from $37.00 to $40.00 and gave the company a buy rating in a research report on Tuesday, April 23rd. Citigroup boosted their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a neutral rating in a research report on Wednesday, April 3rd. Finally, StockNews.com raised Tandem Diabetes Care from a sell rating to a hold rating in a research report on Friday, April 19th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Tandem Diabetes Care presently has an average rating of Moderate Buy and an average price target of $39.45.

Tandem Diabetes Care Stock Performance

TNDM stock opened at $35.24 on Thursday. The stock has a 50-day moving average price of $30.96 and a 200-day moving average price of $25.42. Tandem Diabetes Care has a 1-year low of $13.82 and a 1-year high of $40.74. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91. The firm has a market cap of $2.28 billion, a PE ratio of -10.24 and a beta of 1.12.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The business had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. As a group, equities research analysts expect that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of hedge funds and other institutional investors have recently modified their holdings of the business. MCF Advisors LLC boosted its stake in shares of Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after buying an additional 445 shares during the last quarter. Van ECK Associates Corp boosted its stake in shares of Tandem Diabetes Care by 8.6% in the 4th quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company’s stock worth $175,000 after buying an additional 467 shares during the last quarter. Diversified Trust Co boosted its stake in shares of Tandem Diabetes Care by 5.6% in the 4th quarter. Diversified Trust Co now owns 10,573 shares of the medical device company’s stock worth $313,000 after buying an additional 564 shares during the last quarter. Raymond James & Associates boosted its stake in shares of Tandem Diabetes Care by 1.9% in the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock worth $836,000 after buying an additional 737 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Tandem Diabetes Care by 10.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock worth $205,000 after buying an additional 908 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.